HIV 1 News and Research

RSS

AHF urges all AIDS drug manufacturers to reduce medication cost by 20%

As part of its ongoing advocacy to lower drug prices and increase access to lifesaving medications AIDS Healthcare Foundation, the largest global AIDS organization, today urged all AIDS drug manufacturers to reduce the cost of their medications by 20% for cash-strapped state.

4 Feb 2011

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

Cepheid and FIND today announced a new collaboration to accelerate the development of a rapid molecular test for the measurement of human immunodeficiency virus viral load.

3 Feb 2011

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.

3 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

African first ladies gather to discuss HIV/AIDS

On the sidelines of the African Union Summit in Addis Ababa, Ethiopia, on Monday, the General Assembly of the Organization of African First Ladies Against HIV/AIDS (OAFLA) gathered to discuss the continent's progress against HIV/AIDS, Walta Info reports.

3 Feb 2011

New study examines role of later acquisition of hepatitis C in HIV patients

Hepatitis C is a leading cause of illness and death for individuals infected with both HIV and hepatitis C. Recent reports from around the world demonstrate that hepatitis C is emerging as a sexually transmitted infection among HIV-infected men who do not inject drugs. However, many HIV-infected men do not receive continued screening for hepatitis C throughout their HIV care.

2 Feb 2011

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, "urged developed nations to help him wipe out polio 'once and for all' at an event to release his third annual letter [.pdf] Monday," Agence France-Presse reports.

2 Feb 2011

TEAM TO END AIDS endurance training program launched

AIDS United has officially launched TEAM TO END AIDS, a new endurance training program for all levels of athletes that includes marathon and half marathon coaching. Beginners and experienced athletes can register today at: www.T2EA.com.

2 Feb 2011

Bethany Christian Services creates HIV Adoption Toolkit to educate parents

It is estimated that there are more than one million orphans around the world living with HIV/AIDS. Bethany Christian Services, the nation's largest adoption agency, today announced the creation of the HIV Adoption Toolkit for couples considering adopting children living with HIV/AIDS.

2 Feb 2011

New research: HIV-infected youth get pregnant more often, suffer complications frequently

Teenage girls and young women infected with HIV get pregnant more often and suffer pregnancy complications more frequently than their HIV-negative peers, according to new research led by Johns Hopkins investigators.

2 Feb 2011

Bill Gates argues the case for polio eradication and expanded childhood immunization

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, argues the case for polio eradication and expanded childhood immunization in his third annual letter released today. The letter, a personal account of his priorities, also calls on governments to invest in foreign aid, even in the face of a tough economic climate.

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Current prevention efforts delay but do not prevent HCV among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV.

1 Feb 2011

Viral Genetics enters binding Release and Settlement Agreement with T&T

Viral Genetics, and its President, Haig Keledjian, have entered into a binding Release and Settlement Agreement with Timothy and Thomas LLC and its principals that was approved by the court.

29 Jan 2011

Recent releases in Global Health

Innovative Health Financing Can Benefit Global Health, Pharma: "The launch of pneumococcal vaccination in Nicaragua under AMC [advance market commitment] has shown that innovative approaches to health financing can benefit both global health and pharmaceutical companies," according to a Lancet Infectious Diseases editorial that describes how the roll-out of GAVI initiative is helping to provide developing countries with low-cost pneumococcal vaccines.

28 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

28 Jan 2011

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine Hydrochloride (TMC278), pending its regulatory approval for the treatment of treatment-naive HIV-1-infected adults.

28 Jan 2011

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

In the early years of the AIDS epidemic, being infected with the virus that causes the disease was considered a virtual death sentence. But with the development of antiretroviral therapy, many with HIV are now living much longer. In fact, it is estimated that by 2015, about half of all HIV-positive individuals will be older than 50.

28 Jan 2011

HIV 1 News and Research

AHF urges all AIDS drug manufacturers to reduce medication cost by 20%

Cell signaling hormone boosts immune response to clear HIV-like infection

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

African first ladies gather to discuss HIV/AIDS

New study examines role of later acquisition of hepatitis C in HIV patients

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

TEAM TO END AIDS endurance training program launched

Bethany Christian Services creates HIV Adoption Toolkit to educate parents

New research: HIV-infected youth get pregnant more often, suffer complications frequently

Bill Gates argues the case for polio eradication and expanded childhood immunization

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Current prevention efforts delay but do not prevent HCV among injection drug users

Viral Genetics enters binding Release and Settlement Agreement with T&T

Recent releases in Global Health

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News